Disseminated Bacillus Calmette-Guerin (BCG-osis) in an Immunocompetent Adult After Intravesical BCG Immunotherapy

CHEST Journal ◽  
2014 ◽  
Vol 146 (4) ◽  
pp. 191A ◽  
Author(s):  
Richard May ◽  
Chinenye Emuwa ◽  
Amee Patrawalla ◽  
Andrew Berman
Keyword(s):  
Bacillus Calmette Guerin ◽  
Immunocompetent Adult ◽  
Bcg Immunotherapy ◽  
Intravesical Bcg

scholarly journals Clinical Spectrum of Complications Induced by Intravesical Immunotherapy of Bacillus Calmette-Guérin for Bladder Cancer

2019 ◽  
Vol 2019 ◽  
pp. 1-11 ◽  
Author(s):  
Yuqing Liu ◽  
Jian Lu ◽  
Yi Huang ◽  
Lulin Ma
Keyword(s):  
Bladder Cancer ◽  
Adverse Reactions ◽  
Clinical Manifestations ◽  
Bacillus Calmette Guerin ◽  
Bcg Immunotherapy ◽  
Bcg Therapy ◽  
Intravesical Bcg ◽  
Proven Efficacy ◽  
Bcg Instillation ◽  
Early Establishment

Because of its proven efficacy, intravesical Bacillus Calmette-Guérin (BCG) immunotherapy is an important treatment for nonmuscle invasive bladder cancer at high risk of recurrence or progression. However, approximately 8% of patients have to stop BCG instillation as a result of its complications. Complications induced by BCG therapy can have a variety of clinical manifestations. These adverse reactions may occur in conjunction with BCG instillation or may not develop until months or years after BCG cessation. An essential step in the management complications arising from BCG is early establishment of diagnosis, particularly for distant, disseminated, and obscure infections. Therefore we reviewed the literature on the potential complications after intravesical BCG immunotherapy for bladder cancer and provide an overview on the incidence, diagnosis, and treatment modality of genitourinary and systemic BCG-induced complications.

Bacillus Calmette-Guerin (BCG) balanitis as a complication of intravesical BCG immunotherapy: A case report

1995 ◽  
Vol 27 (3) ◽  
pp. 307-310 ◽  
Author(s):  
A. Erol ◽  
S. Özgür ◽  
N. Tahtali ◽  
E. Akbay ◽  
I. Dalva ◽  
...  
Keyword(s):  
Case Report ◽  
Bacillus Calmette Guerin ◽  
Bcg Immunotherapy ◽  
Intravesical Bcg

scholarly journals Disseminated BCG Infection after intravesical BCG Immunotherapy of Bladder Cancer

QJM ◽  
2021 ◽  
Author(s):  
S Ramalingam ◽  
K Gunasekaran ◽  
H Arora ◽  
M Muruganandam ◽  
S Nagaraju ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Bcg Immunotherapy ◽  
Intravesical Bcg

Recurrent Sigmoid Diverticulitis After Intravesical Bacillus Calmette-Guérin (BCG) Immunotherapy for Bladder Cancer

2021 ◽  
Vol 3 (2) ◽  
pp. 580-583
Author(s):  
Ayesha Kamal ◽  
Furqan Bullar ◽  
Dilhana Badurdeen ◽  
Tinsay Woreta ◽  
Venkata S. Akshintala
Keyword(s):  
Bladder Cancer ◽  
Sigmoid Diverticulitis ◽  
Bacillus Calmette Guerin ◽  
Bcg Immunotherapy

scholarly journals Disseminated Bacillus Calmette–Guérin (BCG) infection and acute exacerbation of interstitial pneumonitis: an autopsy case report and literature review

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Gen Shimizu ◽  
Ryota Amano ◽  
Itaru Nakamura ◽  
Akane Wada ◽  
Masanobu Kitagawa ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bladder Cancer ◽  
Acute Exacerbation ◽  
Interstitial Pneumonitis ◽  
Giant Cells ◽  
Epithelioid Cell ◽  
Bacillus Calmette Guerin ◽  
Antituberculosis Drugs ◽  
First Case ◽  
Intravesical Bcg

Abstract Background Intravesical administration of Bacillus Calmette–Guérin (BCG) has proven useful for treatment and prevention of recurrence of superficial bladder cancer and in situ carcinoma. However, fatal side effects such as disseminated infections may occur. Early diagnosis and accurate therapy for interstitial pneumonitis (IP) are important because exacerbation of IP triggered by infections is the major cause of death. Although some fatality reports have suggested newly appeared IP after intravesical BCG treatment, to our knowledge, there are no reports which have demonstrated acute exacerbation of existing IP. Moreover, autopsy is lacking in previous reports. We report the case of a patient with fatal IP exacerbation after BCG instillation and the pathological findings of the autopsy. Case presentation A 77-year-old man with a medical history of IP was referred to our hospital because of fever and malaise. He had received an intravesical injection of BCG 1 day before the admission. His fever reduced after the use of antituberculosis drugs, so he was discharged home. He was referred to our hospital again because of a high fever 7 days after discharge. On hospitalisation, he showed high fever and systemic exanthema. Hepatosplenomegaly and myelosuppression were also observed. Biopsies revealed multiple epithelioid cell granulomas with Langhans giant cells of the liver and bone marrow. Biopsy DNA analyses of Mycobacterium bovis in the bone marrow, sputum, and blood were negative. His oxygen demand worsened drastically, and the ground-glass shadow expanded on the computed tomography scan. He was diagnosed with acute exacerbation of existing IP. We recommenced the antituberculosis drugs with steroid pulse therapy, but he died on day 35 because of respiratory failure. The autopsy revealed a diffuse appearance of multiple epithelioid cell granulomas with Langhans giant cells in multiple organs, although BCG was not evident. Conclusions We report the first case of acute exacerbation of chronic IP by BCG infection. This is also the first case of autopsy of a patient with acute exacerbation of existing IP induced by intravesical BCG treatment. Whether the trigger of acute IP exacerbation is infection or hypersensitivity to BCG is still controversial, because pathological evidence confirming BCG infection is lacking. Physicians who administer BCG against bladder cancer should be vigilant for acute exacerbation of IP.

A Case of Hepatitis after Intravesical BCG Immunotherapy

2010 ◽  
Vol 23 (2) ◽  
pp. 67-69
Author(s):  
Serife Akalin ◽  
Selmin Caylak ◽  
Demet Okke ◽  
Huseyin Turgut
Keyword(s):  
Bcg Immunotherapy ◽  
Intravesical Bcg

scholarly journals Bacillus Calmette-Guérin (BCG) Infection Following Intravesical BCG Administration as Adjunctive Therapy For Bladder Cancer

Medicine ◽  
2014 ◽  
Vol 93 (17) ◽  
pp. 236-254 ◽  
Author(s):  
María Asunción Pérez-Jacoiste Asín ◽  
Mario Fernández-Ruiz ◽  
Francisco López-Medrano ◽  
Carlos Lumbreras ◽  
Ángel Tejido ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Adjunctive Therapy ◽  
Bacillus Calmette Guerin ◽  
Intravesical Bcg

Possibile ruolo della citofluorometria (CFM) nel monitoraggio della risposta alla terapia endocavitaria con BCG nel carcinoma in situ della vescica: Monitoring the response to intravesical BCG in the treatment of cis: A possible role of flow cytometry

1995 ◽  
Vol 62 (2) ◽  
pp. 245-247
Author(s):  
M. De Siati ◽  
D. Grassi ◽  
N. Franzolin ◽  
L.S. Azzolina
Keyword(s):  
Flow Cytometry ◽  
Carcinoma In Situ ◽  
Recurrent Disease ◽  
Intravesical Therapy ◽  
Urinary Cytology ◽  
Bacillus Calmette Guerin ◽  
Intravesical Bcg

We report our experience on the treatment of carcinoma in situ (CIS) using intravesical therapy with the Bacillus Calmette-Guerin (BCG). From November 1992 to September 1994, 18 patients received treatment: 6 had associated CIS and 12 secondary CIS. Ploidy of each tumour was determined by flow cytometry. Aneuploidy was found in 12 cases, diploidy in 6 cases. After treatment, a standard bladder mapping was performed: 14 patients showed no evidence of cystoscopic and histological disease and if previously aneuploid, became diploid. 4 patients has recurrent disease after therapy; they were all aneuploid before treatment. One of these showed a persistent aneuploidy, although both voided urinary cytology and histological samples were negative. Six months later, a recurrent CIS was seen at the time of cystoscopy. These results enhance the interest in flow cytometry as a possible predictor of response to BCG in the treatment of CIS.

Sign in / Sign up

Export Citation Format

Share Document